Found: 48
Select item for more details and to access through your institution.
Albumin-Mediated Size Exclusion Chromatography: The Apparent Molecular Weight of PSMA Radioligands as Novel Parameter to Estimate Their Blood Clearance Kinetics.
- Published in:
- Pharmaceuticals (14248247), 2022, v. 15, n. 9, p. N.PAG, doi. 10.3390/ph15091161
- By:
- Publication type:
- Article
Preclinical comparison of [<sup>177</sup>Lu]Lu-rhPSMA-10.1 and [<sup>177</sup>Lu]Lu-rhPSMA-10.2 for endoradiotherapy of prostate cancer: biodistribution and dosimetry studies.
- Published in:
- EJNMMI Radiopharmacy & Chemistry, 2024, v. 9, n. 1, p. 1, doi. 10.1186/s41181-024-00246-2
- By:
- Publication type:
- Article
Preclinical biodistribution and dosimetry and human biodistribution comparing <sup>18</sup>F-rhPSMA-7 and single isomer <sup>18</sup>F-rhPSMA-7.3.
- Published in:
- EJNMMI Research, 2022, v. 12, n. 1, p. 1, doi. 10.1186/s13550-021-00872-w
- By:
- Publication type:
- Article
Preclinical comparison of four [18F, natGa]rhPSMA-7 isomers: influence of the stereoconfiguration on pharmacokinetics.
- Published in:
- EJNMMI Research, 2020, v. 10, n. 1, p. 1, doi. 10.1186/s13550-020-00740-z
- By:
- Publication type:
- Article
Cover Feature: Dual‐Nuclide Radiopharmaceuticals for Positron Emission Tomography Based Dosimetry in Radiotherapy (Chem. Eur. J. 3/2018).
- Published in:
- 2018
- By:
- Publication type:
- Cover Art
Dual‐Nuclide Radiopharmaceuticals for Positron Emission Tomography Based Dosimetry in Radiotherapy.
- Published in:
- Chemistry - A European Journal, 2018, v. 24, n. 3, p. 547, doi. 10.1002/chem.201702335
- By:
- Publication type:
- Article
Prostat Kanseri Hastalarinda F-18-RHPSMA-7.3 PET/BT'de Enjekte Edilen Ligand Miktari Biyodağılımı Etkiliyor mu?
- Published in:
- Nuclear Medicine Seminars, 2020, v. 6, p. 47
- By:
- Publication type:
- Article
Validation of <sup>18</sup>F-rhPSMA-7 and <sup>18</sup>F-rhPSMA-7.3 PET Imaging Results with Histopathology from Salvage Surgery in Patients with Biochemical Recurrence of Prostate Cancer.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 12, p. 1809, doi. 10.2967/jnumed.121.263707
- By:
- Publication type:
- Article
Validation of <sup>18</sup>F-rhPSMA-7 and <sup>18</sup>F-rhPSMA-7.3 PET imaging results with histopathology from salvage surgery in patients with biochemical recurrence of prostate cancer.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 10, p. 1, doi. 10.2967/jnumed.121.263707
- By:
- Publication type:
- Article
Utility of <sup>18</sup>F-rhPSMA-7.3 positron emission tomography for imaging of primary prostate cancer and pre-operative efficacy in N-staging of unfavorable intermediate to very high-risk patients validated by histopathology.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 10, p. 1, doi. 10.2967/jnumed.121.263440
- By:
- Publication type:
- Article
Synthesis and Preclinical Evaluation of <sup>177</sup>Lu-labeled Radiohybrid PSMA Ligands (rhPSMAs) for Endoradiotherapy of Prostate Cancer.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 10, p. 1, doi. 10.2967/jnumed.121.263371
- By:
- Publication type:
- Article
<sup>18</sup>F-rhPSMA-7 PET for the Detection of Biochemical Recurrence of Prostate Cancer after Curative-intent Radiation Therapy: A Bicentric Retrospective Study.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 10, p. 1, doi. 10.2967/jnumed.121.262861
- By:
- Publication type:
- Article
Validation of <sup>18</sup>F-rhPSMA-7 and <sup>18</sup>F-rhPSMA-7.3 PET imaging results with histopathology from salvage surgery in patients with biochemical recurrence of prostate cancer.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 9, p. 1, doi. 10.2967/jnumed.121.263707
- By:
- Publication type:
- Article
Utility of <sup>18</sup>F-rhPSMA-7.3 positron emission tomography for imaging of primary prostate cancer and pre-operative efficacy in N-staging of unfavorable intermediate to very high-risk patients validated by histopathology.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 9, p. 1, doi. 10.2967/jnumed.121.263440
- By:
- Publication type:
- Article
Synthesis and Preclinical Evaluation of <sup>177</sup>Lu-labeled Radiohybrid PSMA Ligands (rhPSMAs) for Endoradiotherapy of Prostate Cancer.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 9, p. 1, doi. 10.2967/jnumed.121.263371
- By:
- Publication type:
- Article
<sup>18</sup>F-rhPSMA-7 PET for the Detection of Biochemical Recurrence of Prostate Cancer after Curative-intent Radiation Therapy: A Bicentric Retrospective Study.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 9, p. 203, doi. 10.2967/jnumed.121.262861
- By:
- Publication type:
- Article
<sup>18</sup>F-rhPSMA-7 PET for the Detection of Biochemical Recurrence of Prostate Cancer after Curative-intent Radiation Therapy: A Bicentric Retrospective Study.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 8, p. 203, doi. 10.2967/jnumed.121.262861
- By:
- Publication type:
- Article
Validation of <sup>18</sup>F-rhPSMA-7 and <sup>18</sup>F-rhPSMA-7.3 PET imaging results with histopathology from salvage surgery in patients with biochemical recurrence of prostate cancer.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 7, p. 1, doi. 10.2967/jnumed.121.263707
- By:
- Publication type:
- Article
Utility of <sup>18</sup>F-rhPSMA-7.3 positron emission tomography for imaging of primary prostate cancer and pre-operative efficacy in N-staging of unfavorable intermediate to very high-risk patients validated by histopathology.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 7, p. 1, doi. 10.2967/jnumed.121.263440
- By:
- Publication type:
- Article
Synthesis and Preclinical Evaluation of <sup>177</sup>Lu-labeled Radiohybrid PSMA Ligands (rhPSMAs) for Endoradiotherapy of Prostate Cancer.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 7, p. 1, doi. 10.2967/jnumed.121.263371
- By:
- Publication type:
- Article
<sup>18</sup>F-rhPSMA-7 PET for the Detection of Biochemical Recurrence of Prostate Cancer after Curative-intent Radiation Therapy: A Bicentric Retrospective Study.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 7, p. 1, doi. 10.2967/jnumed.121.262861
- By:
- Publication type:
- Article
Utility of <sup>18</sup>F-rhPSMA-7.3 positron emission tomography for imaging of primary prostate cancer and pre-operative efficacy in N-staging of unfavorable intermediate to very high-risk patients validated by histopathology.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 6, p. 1, doi. 10.2967/jnumed.121.263440
- By:
- Publication type:
- Article
Synthesis and Preclinical Evaluation of <sup>177</sup>Lu-labeled Radiohybrid PSMA Ligands (rhPSMAs) for Endoradiotherapy of Prostate Cancer.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 6, p. 1, doi. 10.2967/jnumed.121.263371
- By:
- Publication type:
- Article
<sup>18</sup>F-rhPSMA-7 PET for the Detection of Biochemical Recurrence of Prostate Cancer after Curative-intent Radiation Therapy: A Bicentric Retrospective Study.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 6, p. 1, doi. 10.2967/jnumed.121.262861
- By:
- Publication type:
- Article
Validation of <sup>18</sup>F-rhPSMA-7 and <sup>18</sup>F-rhPSMA-7.3 PET imaging results with histopathology from salvage surgery in patients with biochemical recurrence of prostate cancer.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 5, p. 1, doi. 10.2967/jnumed.121.263707
- By:
- Publication type:
- Article
Utility of <sup>18</sup>F-rhPSMA-7.3 positron emission tomography for imaging of primary prostate cancer and pre-operative efficacy in N-staging of unfavorable intermediate to very high-risk patients validated by histopathology.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 5, p. 1, doi. 10.2967/jnumed.121.263440
- By:
- Publication type:
- Article
Synthesis and Preclinical Evaluation of <sup>177</sup>Lu-labeled Radiohybrid PSMA Ligands (rhPSMAs) for Endoradiotherapy of Prostate Cancer.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 5, p. 1, doi. 10.2967/jnumed.121.263371
- By:
- Publication type:
- Article
<sup>18</sup>F-rhPSMA-7 PET for the Detection of Biochemical Recurrence of Prostate Cancer after Curative-intent Radiation Therapy: A Bicentric Retrospective Study.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 5, p. 1, doi. 10.2967/jnumed.121.262861
- By:
- Publication type:
- Article
Utility of <sup>18</sup>F-rhPSMA-7.3 positron emission tomography for imaging of primary prostate cancer and pre-operative efficacy in N-staging of unfavorable intermediate to very high-risk patients validated by histopathology.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 3, p. 1, doi. 10.2967/jnumed.121.263440
- By:
- Publication type:
- Article
Synthesis and Preclinical Evaluation of <sup>177</sup>Lu-labeled Radiohybrid PSMA Ligands (rhPSMAs) for Endoradiotherapy of Prostate Cancer.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 3, p. 1, doi. 10.2967/jnumed.121.263371
- By:
- Publication type:
- Article
Utility of <sup>18</sup>F-rhPSMA-7.3 positron emission tomography for imaging of primary prostate cancer and pre-operative efficacy in N-staging of unfavorable intermediate to very high-risk patients validated by histopathology.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 2, p. 1, doi. 10.2967/jnumed.121.263440
- By:
- Publication type:
- Article
Synthesis and Preclinical Evaluation of <sup>177</sup>Lu-labeled Radiohybrid PSMA Ligands (rhPSMAs) for Endoradiotherapy of Prostate Cancer.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 2, p. 1, doi. 10.2967/jnumed.121.263371
- By:
- Publication type:
- Article
Utility of <sup>18</sup>F-rhPSMA-7.3 positron emission tomography for imaging of primary prostate cancer and pre-operative efficacy in N-staging of unfavorable intermediate to very high-risk patients validated by histopathology.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 1, p. 1, doi. 10.2967/jnumed.121.263440
- By:
- Publication type:
- Article
Pre-therapeutic comparative dosimetry of <sup>177</sup>Lu-rhPSMA-7.3 and <sup>177</sup>Lu-PSMA-I&T in patients with metastatic castration resistant prostate cancer (mCRPC).
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 12, p. 1, doi. 10.2967/jnumed.121.262671
- By:
- Publication type:
- Article
The Influence of Specific Activity on the Biodistribution of <sup>18</sup>F-rhPSMA-7.3: A Retrospective Analysis of Clinical Positron Emission Tomography Data.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 12, p. 1, doi. 10.2967/jnumed.121.262475
- By:
- Publication type:
- Article
Pre-therapeutic comparative dosimetry of <sup>177</sup>Lu-rhPSMA-7.3 and <sup>177</sup>Lu-PSMA-I&T in patients with metastatic castration resistant prostate cancer (mCRPC).
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 11, p. 1, doi. 10.2967/jnumed.121.262671
- By:
- Publication type:
- Article
Pre-therapeutic comparative dosimetry of <sup>177</sup>Lu-rhPSMA-7.3 and <sup>177</sup>Lu-PSMA-I&T in patients with metastatic castration resistant prostate cancer (mCRPC).
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 10, p. 1, doi. 10.2967/jnumed.121.262671
- By:
- Publication type:
- Article
The Influence of Specific Activity on the Biodistribution of <sup>18</sup>F-rhPSMA-7.3: A Retrospective Analysis of Clinical Positron Emission Tomography Data.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 10, p. 1, doi. 10.2967/jnumed.121.262471
- By:
- Publication type:
- Article
Comparative Preclinical Biodistribution, Dosimetry, and Endoradiotherapy in Metastatic Castration-Resistant Prostate Cancer Using <sup>19</sup>F/<sup>177</sup>Lu-rhPSMA-7.3 and <sup>177</sup>Lu-PSMA I&T.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 8, p. 1106, doi. 10.2967/jnumed.120.254516
- By:
- Publication type:
- Article
BRIEF COMMUNICATION: The Influence of Specific Activity on the Biodistribution of <sup>18</sup>F-rhPSMA-7.3: A Retrospective Analysis of Clinical Positron Emission Tomography Data.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 8, p. 1, doi. 10.2967/jnumed.121.262471
- By:
- Publication type:
- Article
Positive predictive value and correct detection rate of <sup>18</sup>F-rhPSMA-7 PET in biochemically recurrent prostate cancer validated by composite reference standard.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 12, p. 1, doi. 10.2967/jnumed.120.255661
- By:
- Publication type:
- Article
Matched-pair comparison of <sup>68</sup>Ga-PSMA-11 and <sup>18</sup>F-rhPSMA-7 PET/CT in patients with primary and biochemical recurrence of prostate cancer: frequency of non-tumor related uptake and tumor positivity.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 12, p. 1, doi. 10.2967/jnumed.120.251447
- By:
- Publication type:
- Article
Radiohybrid ligands: a novel tracer concept exemplified by <sup>18</sup>F- or <sup>68</sup>Ga-labeled rhPSMA-inhibitors.
- Published in:
- Journal of Nuclear Medicine, 2019, v. 60, n. 12, p. 1, doi. 10.2967/jnumed.119.234922
- By:
- Publication type:
- Article
<sup>18</sup>F‐rhPSMA‐7 positron emission tomography for the detection of biochemical recurrence of prostate cancer following radical prostatectomy.
- Published in:
- Journal of Nuclear Medicine, 2019, v. 60, n. 12, p. 1, doi. 10.2967/jnumed.119.234914
- By:
- Publication type:
- Article
1Histologically-confirmed diagnostic efficacy of <sup>18</sup>F-rhPSMA-7 positron emission tomography for N-staging of patients with primary high risk prostate cancer.
- Published in:
- Journal of Nuclear Medicine, 2019, v. 60, n. 12, p. 1, doi. 10.2967/jnumed.119.234906
- By:
- Publication type:
- Article
Quantitative and Qualitative Analyses of Biodistribution and PET Image Quality of Novel Radiohybrid PSMA, <sup>18</sup>F- rhPSMA-7, in Patients with Prostate Cancer.
- Published in:
- Journal of Nuclear Medicine, 2019, v. 60, n. 12, p. 1, doi. 10.2967/jnumed.119.234609
- By:
- Publication type:
- Article
Synthesis and Preclinical Characterization of the PSMA-Targeted Hybrid Tracer PSMA-I&F for Nuclear and Fluorescence Imaging of Prostate Cancer.
- Published in:
- Journal of Nuclear Medicine, 2019, v. 60, n. 1, p. 71, doi. 10.2967/jnumed.118.212720
- By:
- Publication type:
- Article
Automated synthesis of [18F]Ga-rhPSMA-7/ -7.3: results, quality control and experience from more than 200 routine productions.
- Published in:
- EJNMMI Radiopharmacy & Chemistry, 2021, v. 6, n. 1, p. 1, doi. 10.1186/s41181-021-00120-5
- By:
- Publication type:
- Article